title: Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
abstract: OBJECTIVE
  To investigate the relationship between the expression of LSD1 and E-cadherin in prostate cancer and their prognostic significance.
  
  
  METHODS
  The expression of LSD1 and E-cadherin in prostate cancer was detected using immunohistochemistry, and the relationship between the expressions of these two molecules was analyzed by correlation analysis. Furthermore, LNCap cell line was treated with Pargyline (an inhibitor of LSD1), and Western blot was used to analyze LSD1 and E-cadherin expression.
  
  
  RESULTS
  LSD1 expression increased significantly in prostate cancer specimens compared with benign prostatic hyperplasia (P < 0.05). Further analysis testified that LSD1 expression was positively correlated with higher Gleason Score, distant metastases, and poor prognosis (P < 0.05). Nevertheless, E-cadherin expression decreased significantly in prostate cancer specimens compared with benign prostatic hyperplasia (P < 0.05) and was negatively correlated with higher Gleason Score, distant metastases (P < 0.05). Correlation analysis revealed that LSD1 expression was negatively correlated with E-cadherin expression in prostate cancer (rs = -0.486, P = 0.001). Positive LSD1 expression and negative E-cadherin expression were significantly correlated with high 2-year progression (occurrence of castration-resistant prostate cancer) rate and low 5-year survival rate (P < 0.05). Moreover, Pargyline inhibited activity of LSD1 and up-regulated E-cadherin expression.
  
  
  CONCLUSIONS
  High LSD1 expression combined with low E-cadherin expression might be predictors of prostate cancer progression and metastasis. Inhibition of LSD1 may be a potential therapeutic target for prevention of prostate cancer.
authors: Department of Urology, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan, 430060, Hubei, People's Republic of China, drwangmin@163.com.
authors: Min
authors: M
authors: Wang
authors: Xiuheng
authors: X
authors: Liu
authors: Guanjun
authors: G
authors: Jiang
authors: Hui
authors: H
authors: Chen
authors: Jia
authors: J
authors: Guo
authors: Xiaodong
authors: X
authors: Weng
mesh_terms: D015820:Cadherins / Q000032:analysis* / Q000187:drug effects; D002277:Carcinoma / Q000737:chemistry* / Q000556:secondary; D045744:Cell Line, Tumor; D018450:Disease Progression; D056466:Histone Demethylases / Q000032:analysis* / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D010293:Pargyline / Q000494:pharmacology; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology
chemical_list: D015820:Cadherins; D010293:Pargyline; D056466:Histone Demethylases; C495195:KDM1A protein, human
references: Acta Anat (Basel). 1995;154(1):8-20
references: 8714286
references: Cancer Res. 2006 Dec 1;66(23):11341-7
references: 17145880
references: Cancer Lett. 2012 May 28;318(2):162-72
references: 22182447
references: Cancer Res. 2006 Mar 1;66(5):2815-25
references: 16510604
references: Nature. 2010 Apr 1;464(7289):792-6
references: 20228790
references: Curr Genomics. 2009 Mar;10(1):18-25
references: 19721807
references: Am J Pathol. 1994 Apr;144(4):735-46
references: 7512791
references: Oncogene. 2010 Sep 2;29(35):4896-904
references: 20562920
references: Cell. 2009 Nov 25;139(5):871-90
references: 19945376
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Cancer Res. 2009 Mar 1;69(5):2065-71
references: 19223552
references: Nat Cell Biol. 2000 Feb;2(2):84-9
references: 10655587
references: Int J Cancer. 2011 Feb 1;128(3):574-86
references: 20333681
references: Nature. 2005 Sep 15;437(7057):436-9
references: 16079795
references: Pathologe. 1987 May;8(3):138-40
references: 3303008
references: Cell. 2009 Aug 21;138(4):645-659
references: 19682730
references: Dig Dis Sci. 2013 Jun;58(6):1581-9
references: 23314859
references: Cell. 2011 Nov 23;147(5):992-1009
references: 22118458
references: Clin Cancer Res. 2004 Jan 15;10(2):440-8
references: 14760063
references: Cell. 2008 May 16;133(4):704-15
references: 18485877
references: Int J Cancer. 1991 May 10;48(2):189-93
references: 1708363
references: Cell Biol Toxicol. 2010 Dec;26(6):553-67
references: 20397042
references: J Biol Chem. 2007 May 25;282(21):15471-5
references: 17409384
references: Cancer Sci. 2010 Feb;101(2):293-9
references: 19961486
references: Hum Pathol. 2012 Aug;43(8):1300-7
references: 22245111
references: Cell. 2004 Dec 29;119(7):941-53
references: 15620353
references: FASEB J. 2010 Mar;24(3):769-77
references: 19901020
references: Biochim Biophys Acta. 2009 Dec;1796(2):75-90
references: 19306912
references: J Cell Biochem. 2004 Feb 15;91(3):483-90
references: 14755679
references: Nature. 2007 Sep 6;449(7158):105-8
references: 17805299
references: Am J Pathol. 2004 Jan;164(1):217-27
references: 14695335
references: N Engl J Med. 1995 May 25;332(21):1393-8
references: 7723794
references: Mol Carcinog. 2011 Dec;50(12):931-44
references: 21400613
references: EMBO J. 2010 Jun 2;29(11):1803-16
references: 20389281